ACADIA Pharmaceuticals Inc.

Healthcare · Biotechnology · United States

Last price 20.59 USD (Oct 30, 2026, 4:00 PM EDT) · Market cap 3.55B

Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports

Acadia Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of medicines for neurological and rare disease in North America. The company offers NUPLAZID (pimavanserin), a selective serotonin inverse agonist/antagonist for the treatment of hallucinations and delusions associated with Parkinson’s disease psychosis; and DAYBUE, a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 to treat the symptoms of Rett syndrome by reducing neuroinflammation and supporting sy...